Modality
mRNA
MOA
PI3Ki
Target
CD47
Pathway
Innate Imm
OCD
Development Pipeline
Preclinical
~Jun 2015
→ ~Sep 2016
Phase 1
~Dec 2016
→ ~Mar 2018
Phase 2
~Jun 2018
→ ~Sep 2019
Phase 3
~Dec 2019
→ ~Mar 2021
NDA/BLA
~Jun 2021
→ ~Sep 2022
Approved
Dec 2022
→ Apr 2028
ApprovedCurrent
NCT05138539
823 pts·OCD
2022-12→2028-04·Not yet recruiting
823 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2028-04-262.1y awayPh3 Readout· OCD
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
Approved
Not yet…
Catalysts
Ph3 Readout
2028-04-26 · 2.1y away
OCD
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05138539 | Approved | OCD | Not yet recr... | 823 | BodyWt |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8903 | Eli Lilly | Preclinical | CD47 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| GSK-4334 | GSK | Preclinical | CD47 | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| BMR-1165 | BioMarin | Phase 2 | CD47 |